Stone JD, Holt AW, Vuncannon JR, Brault JJ, Tulis DA. AMP-activated protein kinase inhibits transforming growth factor-␤-mediated vascular smooth muscle cell growth: implications for a Smad-3-dependent mechanism.
CARDIOVASCULAR DISEASE (CVD) is the number one cause of fatality in the United States and worldwide, and according to the American Heart Association abnormal vascular smooth muscle (VSM) growth is a key underpinning for many of these pathologies (6) . Despite ample research the molecular events leading to mitogenic activation of vascular smooth muscle cells (VSMCs) and their ensuing involvement in CVD pathogenesis are not fully understood.
Adenosine monophosphate-activated protein kinase (AMPK) is a constitutively expressed serine/threonine kinase that responds to a rise in AMP/ATP under metabolic challenge (8, 17, 20) . Activation of AMPK requires AMP binding and catalytic phosphorylation (17, 20) and leads to energy-producing pathways being upregulated while energy-consuming pathways are shut off or rendered minimally active (7, 8, 17, (22) (23) (24) . AMPK has many tissue-dependent functional targets leading to phosphorylation of key metabolic enzymes and, specifically in the vasculature, has been implicated in increased endothelial nitric oxide synthase activity and nitric oxide bioavailability, the promotion of angiogenesis, and cytostasis of commercial and primary VSMCs via inhibition of cell cycle progression (10, 13, (22) (23) (24) . Moreover, AMPK activation has been shown to inhibit neointima formation in rat arteries following injury (13, 23) . Together, these studies suggest growth-regulatory capacity by AMPK; however, specific mechanisms of AMPK in VSMCs, particularly related to proliferation and migration, remain elusive. Of these, the role that AMPK may play in the inhibition of cell proliferation under cytokine stimulation during disease is especially intriguing and is critical for a better understanding of vascular and associated proliferative pathologies.
Transforming growth factor-␤1 (TGF-␤1) is a multifunctional cytokine acting canonically through Smad signaling to exert effects in a wide range of cell types. In VSMCs, TGF-␤ has historically been considered antiproliferative (2, 14 -16) ; however, other findings suggest that TGF-␤ and its downstream Smads stimulate growth in primary VSMCs (9, 18, 19, (25) (26) (27) . Adding to this uncertainty, in cultured cells TGF-␤1 is suggested to switch between growth stimulation and growth suppression depending on concentration (3, 18) and cell density (9) . This pleiotropic and often discordant nature of TGF-␤/Smad signaling and its control of tissue growth demand clarity.
TGF-␤ elicits effects by binding to cell surface receptors, whereupon it stimulates phosphorylation of cytoplasmic receptor-activated Smads (R-Smads), Smad2 and Smad3, that combine with common Smad4, and the oligomer translocates to the nucleus where it activates growth regulatory genes (18, 21, 26, 28) . Another component of this signal transduction pathway is inhibitory Smad7 that suppresses TGF-␤ signaling by interfering with activation of the R-Smads (18, 21, 28) . The growthstimulating capacity of TGF-␤ in VSMCs has recently been suggested to involve Smad3-mediated phosphorylation and nuclear export of p27, a cyclin-dependent kinase inhibitor (27) . The many uncertain aspects of TGF-␤/Smad signaling, particularly in VSM, justify continued study and present an attractive target for future therapeutic interests.
To date, no studies have examined the potential role of AMPK in modulating TGF-␤-induced VSMC growth. Based on our previous observations showing growth inhibition by AMPK in VSM (23, 24) , and considering the potential growthpromoting nature of TGF-␤/Smad3 in VSM, an interesting yet unexplored relationship may exist between these two signaling molecules. The purpose of this investigation was to characterize the capacity of AMPK to modulate growth in response to TGF-␤ in rat VSMCs. We hypothesized that AMPK has the capacity to reduce TGF-␤-stimulated VSMC growth via reduction in Smad signaling and inhibition of cell cycle regulatory proteins. Novel results shed light on the relationship between AMPK and TGF-␤/Smads in VSM and provide support for continued investigation of AMPK as a valuable target for therapies aimed at reducing vascular growth disorders.
MATERIALS AND METHODS
This investigation was approved by the East Carolina University Animal Care and Use Committee (U.S. National Institutes of Health, Publication No. 85-23, revised 1996).
Materials
AICAR was purchased from Toronto Research Chemicals (North York, Ontario) and Invitrogen (Carlsbad, CA). Recombinant TGF-␤1 was purchased from R&D Systems (Minneapolis, MN). All primary antibodies were purchased from Abcam (Cambridge, MA) or Cell Signaling (Danvers, MA), were diluted 1:1,000 for In-Cell Western or 1:500 for immunofluorescence detected by flow cytometry and iCys laser-scanning cytometric (LSC) analysis, and were targeted against the following: Smad2, pSmad2 Thr 8, Smad3, pSmad3Ser423/425, Smad7; cyclin D, cyclin E, cyclin-dependent kinase (CDK) 2, CDK4, CDK6, p21, p27; ␣-tubulin, and ␤-actin. Antibodies were diluted in IRDye blocking buffer (Rockland, Gilbertsville, PA) or 1% BSA in PBS (Gemini, Stoneham, MA). IRDye secondary antibodies (1:1,000; Rockland) and FITC-or Texas red-conjugated secondary antibodies (1:10,000; Rockland) were used for protein detection while Draq 5 (1:10,000; Cell Signaling) and Sapphire 700 (1:1,000; Li-Cor, Lincoln, NE) were used for DNA staining and protein normalization, respectively. Propidium iodide and RNase or DRAQ5 for cell cycle analysis with flow cytometry and DAPI for cell cycle analysis with iCys LSC were purchased from Invitrogen. Adenoviruses (type 5) encoding GFP (Ad-GFP) or Smad3 (Ad-Smad3) were purchased from Vector Biolabs (Philadelphia, PA).
Methods
Cell culture. Rat thoracic aorta VSMCs (A7r5) were purchased from ATCC (Manassas, VA). Primary VSMCs were obtained from thoracic aorta of male Sprague Dawley rats (ϳ125 g; Charles River Labs) by collagenase and elastase digestion and characterized morphologically as described (5) . VSMCs were cultured in Dulbecco's modified Eagles medium (DMEM) supplemented with fetal bovine serum (FBS, 0.5-10%), 2 mM L-glutamine, and 1:500 dilution of 50 g/ml Primocin at 37°C in 95% air-5% CO 2, and were serially split and used through passage 10 (commercial) or passage 6 (primary) to avoid onset of phenotypic switching (1, 11, 23, 24) unless otherwise stated.
Protein detection. IN-CELL WESTERN. VSMCs were seeded in 96-well plates and, once confluent, were treated with specified agents. Cells were then formalin fixed, and protein expression was determined by In-Cell Western analysis as described (1, 11, 24) . Briefly, fixed cells were permeabilized with 0.1% Triton X, blocked with IRDye blocking buffer (Invitrogen), and treated with rabbit antirat primary antibodies (1 h; room temperature) in 96-well plates. Primary antibodies targeting specific proteins were detected using antirabbit secondary antibodies conjugated with an IR800 fluorophore, and DNA was stained using DRAQ5 and Sapphire700 and used for normalization. Fluorescence was detected and quantified at 800 nm and DNA at 700 nm using a Li-Cor Odyssey Infrared Imaging System and analysis software.
IMMUNOFLUORESCENCE WITH FLOW CYTOMETRY. Confluent VSMCs were treated with select pharmacological agents for 1-24 h and then trypsinized, fixed with 4% formalin, washed with PBS, permeabilized with 0.1% Triton X in PBS, washed, and blocked with 1% BSA in PBS. Select proteins were detected by primary/secondary antibody conjugation in 1% BSA and analyzed by flow cytometry (Accuri C6 Flow Cytometer) using CFlow Plus software (Accuri).
Cell cycle analysis. Cells were plated in 12-well plates at 80,000 cells/well in complete media until ϳ50% confluent. Cells were quiesced in 0.5% FBS for 24 h followed by treatment in complete growth media (DMEM, 10% FBS; Primocin) containing select pharmacological agents for 24 h. Cells were trypsinized, fixed, and stained with propidium iodide or Draq5 for flow cytometry or DAPI for iCys per the manufacturer's recommendations (11, 24) . The fraction of cells in each phase of the cell cycle was assessed by flow cytometry or iCys LSC.
Cell proliferation and viability analyses. VSMCs were plated in six-well plates at 180,000 cells/well, 12-well plates at 50,000 cell/ well, or Ibidi 6.4 slides at 25,000 cells/channel in complete media until ϳ50% confluent. Cells were quiesced in 0.5% FBS for 24 h followed by treatment in complete growth media for 48 h. For LSC analysis, cells were fixed and stained with DAPI, and cell cycle progression was determined through iCys LSC software. Proliferation and viability of suspended cells were accomplished through automated cell counting using trypan blue exclusion staining (ViCell; Beckman Coulter).
Adenovirus overexpression of Smad3. Adenoviral titers incorporating GFP or Smad3 (4 ϫ 10 10 and 1 ϫ 10 10 plaque formation units/ml, respectively) were determined using the end-point dilution assay previously described (4) . Sufficient protein expression in the absence of cytotoxicity was observed after infecting VSMCs for 6 h using Ad-GFP at a 1:10,000 dilution followed by washout and 24 h incubation in complete media. Cell viability was determined using trypan blue exclusion 42 h after virus washout.
Statistical Analyses
Data were analyzed using Excel 2011 (Microsoft) and Sigma Plot 11.2 (SPSS). All datasets were tested for normal distribution and met the homogeneity prerequisites for analysis of variance (ANOVA). One-way ANOVA and Tukey's post hoc multiple-comparison tests were used to detect changes between individual groups. Two-way ANOVA with multiple comparisons and Tukey's post hoc tests were used for cell cycle analysis to detect significance between groups. Data are expressed as means Ϯ SE with P Ͻ 0.05 considered statistically significant.
RESULTS

TGF-␤ Promotes VSMC Growth
Our initial series of experiments aimed to verify capacity of TGF-␤1 to induce Smad signaling and to regulate growth in rat VSMCs. To determine the lowest bioactive concentration of recombinant TGF-␤1 (rTGF-␤1) in VSMCs, serial dosing experiments were performed on two different preparations: commercial A7R5 cells (Fig. 1A ) and rat primary cells (Fig.  1B) . In both cases, 10 ng/ml rTGF-␤1 was the lowest concentration that yielded the maximal effect on Smad3 phosphorylation and thus was the rTGF-␤1 concentration used in subsequent experiments. Also, given these comparable responses in commercial vs. primary cells in rTGF-␤1-induced Smad3 phosphorylation as well as parallel growth responses to rTGF-␤1 with/without AICAR (discussed below), commercial VSMCs were used in all experiments unless otherwise specified. Cells were then treated with rTGF-␤1 (60 min), and Smad2, Smad3, and Smad7 were analyzed. Results showed significantly elevated levels of phosphorylated Smad2 (at Thr 8 ) and Smad3 (at Ser 423/425 ) as well as moderately (Ϸ20%; P ϭ 0.35) decreased expression of Smad7 in rTGF-␤1-treated cells compared with vehicle controls (Fig. 2) . Treatment with rTGF-␤1 significantly increased cell numbers in the G 2 /M phase of the cell cycle in both commercial (Fig. 3A) and primary ( Fig. 3C ) cells after 24 h, and significantly elevated viable cell numbers in commercial (Fig. 3B) and primary (Fig.  3D ) cells after 48 h compared with respective vehicle controls. Treatment with rTGF-␤1 significantly increased growth-promoting cyclins D1 and E (Fig. 4, A and B) and the catalytic CDK2 and CDK4 (Fig. 4, C and D) compared with vehicle controls, yet only marginally reduced expression of the CDK inhibitors (CDK-I) p21 and p27 compared with vehicle controls (Fig. 4, F and G) .
AICAR Inhibits TGF-␤1-Induced VSMC Growth Via Inhibition of Smad Signaling
We recently demonstrated that activation of AMPK via the AMP mimetic AICAR (1 mM) effectively reduces proliferation and migration of rat VSMCs (23, 24) . Therefore, in an effort to examine the influence of AMPK on the observed TGF-␤1/Smad-induced VSMC growth, VSMCs were treated with AICAR (1 mM in all experiments) in the presence or absence of rTGF-␤1 and Smad signals, and indexes of vascular growth were evaluated. As shown in Fig. 2 , AICAR alone had modest effects on pSmad2 and pSmad3 (normalized to total Smad2 or Smad3, respectively), yet significantly increased Smad7 levels compared with vehicle controls. Interestingly, in the presence of rTGF-␤1, AICAR significantly and completely reversed the increases in pSmad2 and pSmad3 observed with rTGF-␤1 alone and sustained significant increases in Smad7 (Fig. 2) .
In line with our previous observations (23, 24) , sole AICAR treatment induced significant increases in S phase cell numbers, significantly reduced G 2 /M phase cell numbers after 24 h (Fig. 3A) , and significantly reduced viable cell numbers after 48 h (Fig. 3B ) in commercial VSMCs compared with vehicle controls, and analogous findings were observed in primary cells (Fig. 3, C and D) . Moreover, AICAR completely reversed the increases in G 2 /M cell numbers observed with rTGF-␤1 alone after 24 h (Fig. 3, A and C) and completely abrogated the rTGF-␤1-induced increases in viable cell numbers at 48 h (Fig.  3, B and D) in both VSMC preparations. No significant changes were observed in G 0 /G 1 at 24 h or in cell viability at 48 h (P ϭ 0.08; data not shown) following rTGF-␤1 with/ without AICAR.
AICAR Reverses TGF-␤1-Mediated Alterations in Cell Cycle Regulatory Proteins
To determine possible mechanisms by which AMPK inhibits TGF-␤1-induced cell growth, we investigated expression of the key cell cycle regulators observed to be altered by rTGF-␤1 in the presence of AICAR. AICAR alone had no effect on cyclin expression (Fig. 4, A and B) ; however, a nonsignificant trend for reduction of CDK2 (P ϭ 0.07; Fig. 4C ) and a significant reduction in CDK4 (Fig. 4D) were observed in nonstimulated cells. Intriguingly, in stimulated cells, AICAR reversed rTGF-␤1-induced increases in cyclins D1 and E and CDK2 and CDK4 (Fig. 4, A-D, respectively) . Additionally, AICAR significantly increased p21 expression under both nonstimulated and rTGF-␤1-stimulated conditions (Fig. 4F) , while only under nonstimulated conditions did AICAR significantly increase p27 content (Fig. 4G) .
Smad3 Specifically Increases VSMC Growth
In an effort to determine if TGF-␤1 acts through canonical Smad3 to elevate VSMC growth, we used an adenovirus to overexpress Smad3 as we previously described (4). Figure 5 shows significantly increased expression of GFP (Ad-GFP; Fig. 5A ; photomicrograph shows positive GFP staining in Ad-GFP-infected cells) or Smad3 (Ad-Smad3; Fig. 5B ) compared with vehicle controls after 24 h. As before, we analyzed cell cycle progression and viable cell numbers of Smad3-infected VSMCs with/without AICAR. Smad3 overexpression induced cell cycle progression by reducing the number of cells in G 0 /G 1 and significantly increasing the number of cells in G 2 /M compared with Ad-GFP controls (Fig. 5C) ; however, concomitant incubation of cells with AICAR fully reversed these observations (Fig. 5C ). Moreover, Ad-Smad3 increased viable cell numbers after 48 h compared with Ad-GFP controls, and this too was completely reversed with concomitant AICAR (Fig. 5D) .
To verify that transient Smad3 overexpression was causative for the reversal of rTGF-␤1-mediated VSMC growth by AICAR, we serially passaged Ad-GFP and Ad-Smad3 cells (to between passages 3 and 6 following infection) and performed immunofluorescence for Smad3 content and cell cycle analysis. Expression of GFP and total Smad3 as well as Ad-Smad3-mediated stimulation of cell cycle progression returned to control levels after repeated passaging of VSMCs (data not shown).
DISCUSSION
Data presented in this study support the hypothesis that AMPK inhibits VSM growth through a mechanism at least partly dependent on TGF-␤/Smad signals. Novel findings show that the metabolic regulator AMPK, stimulated to biologically active levels by AICAR as demonstrated recently (23, 24) , serves to reduce TGF-␤/Smad signaling and its growth-stimulating effects in rat VSMCs. These findings are among the first to suggest that AMPK inhibits VSMC growth associated with the proliferative and synthetic TGF-␤ signaling network. Data presented here in conjunction with our recently published findings (23, 24) provide unique insights into AMPK signaling as a biologically capable system to offer remediation of vascular growth, including that induced by TGF-␤/Smad.
In light of previously reported controversial findings, results from this research support the capacity of TGF-␤ to increase VSMC growth evidenced through cell cycle progression and cell proliferation analyses. Recombinant TGF-␤ alone significantly increased cell numbers entering the G 2 /M phase after 24 h (Fig. 3, A and C) and induced an ϳ50% increase in viable cell numbers after 48 h (Fig. 3, B and D) . Moreover, Smad3 overexpression (Fig. 5B ) produced similar and significant increases in cell numbers in G 2 /M as well as viable cell numbers (Fig. 5, C and D) . Importantly, in both rTGF-␤-stimulated cells and Smad3-overexpressing cells AICAR was able to significantly reduce cell cycle progression revealed by reduced cell numbers in G2/M after 24 h (Figs. 3A and 5C ) and reduced cell numbers after 48 h (Figs. 3B and 5D ) compared with rTGF-␤ Moreover, our results provide insights suggesting that TGF-␤ acts, at least in part, in a Smad3-dependent fashion and that AMPK has the ability to reduce TGF-␤-induced VSM growth in a Smad3-dependent manner. This does not rule out the possibility, though, that AMPK via AICAR may have non-TGF-␤/Smad actions in VSM. Nonetheless, because VSMC growth and migration are foundational in the progression of vascular growth disorders, implication of AMPK as an inhibitor of TGF-␤ signaling has great biological impact. To determine possible mechanisms by which AMPK inhibits TGF-␤/Smad3 signaling and cellular growth, we investigated the influence of AICAR on the TGF-␤/Smad network. Figure   2 demonstrates that, while AICAR alone had no effect on expression of pSmad2 or pSmad3, in rTGF-␤-stimulated cells AICAR completely reversed phosphorylation of both Smad2 and Smad3. Additionally, both stimulated and nonstimulated VSMCs showed significant increases in the expression of inhibitory Smad7 when treated with AICAR. These data suggest that, while under basal conditions AMPK may play little or no role in regulating TGF-␤ signaling, under cytokineinduced growth-provoking conditions, AMPK plays a key inhibitory role on TGF-␤ at least in part through the inhibitory actions of Smad7. An increase in Smad7 inhibits oligomerization of pSmad2/pSmad3 with cytoplasmic Smad4. In addition, Fig. 4 . AICAR controls TGF-␤1-induced cell cycle regulatory proteins. Rat A7R5 VSMCs were treated with vehicle or rTGF-␤1 (10 ng/ml) with/without AICAR (1 mM) for 24 h following overnight quiescence, and cell cycle regulatory proteins cyclin D1 and cyclin E, the cyclin-dependent kinases (CDK) 2, CDK4, and CDK6, and the cyclin-dependent kinase inhibitors (CDK-I) p21 and p27 were analyzed by immunofluorescence with flow cytometry. Treatment with rTGF-␤1 alone significantly increased expression of cyclin D1 (A) and cyclin E (B), and these were reversed in the presence of AICAR. AICAR alone did not significantly alter expression of cyclins D1 or E compared with vehicle controls. Treatment with rTGF-␤1 alone induced expression of the cyclin E/cyclin A agonist CDK2 (C) and the cyclin D agonist CDK4 (D) compared with vehicle controls, and both were significantly reversed in the presence of AICAR. AICAR alone modestly (nonsignificantly) reduced CDK2 and significantly reduced CDK4 expression compared with controls, yet no changes were observed in CDK6 expression with any TGF-␤1/AICAR regimen (E). Treatment with TGF-␤1 alone failed to significantly alter p21 (F) or p27 (G) expression compared with vehicle controls, yet sole AICAR treatment induced significant elevations in both p21 and p27 compared with controls. Concomitant TGF-␤1 and AICAR reversed p27 induction observed with TGF-␤1 treatment alone but did not markedly alter TGF-␤1-induced p21 induction. Data are presented as protein of interest normalized to total protein, with n ϭ 3-5/treatment group. P values Ͻ 0.05 were considered statistically significant. *P Ͻ 0.05, **P Ͻ 0.005, and ***P Ͻ 0.001 compared with vehicle controls, #P Ͻ 0.05 compared with the TGF-␤1 treatment group, and ⌬P Ͻ 0.05 compared with AICAR treatment alone. a recent report by Zhao et al. (29) showed that AMPK can inhibit nuclear translocation of Smad4 via reduction of Smad4 expression. Taken together, these data strongly suggest that AMPK can inhibit translocation of the Smad oligomer into the nucleus thus inhibiting activation of TGF-␤-dependent progrowth gene transcription (18, 21, 29) . These findings, in light of our cytostatic data, suggest AMPK-mediated inhibition of TGF-␤ signal transduction further occurs by increasing cytoplasmic Smad7 thereby indirectly reducing cell cycle progression and cell proliferation.
In this study we also investigated the cytostatic role of AMPK on TGF-␤-stimulated VSMCs by examining cell cycle regulatory proteins. Early G 0 /G 1 -dependent cyclin D and late G 0 /G 1 -dependent cyclin E were both significantly elevated by rTGF-␤; however, concomitant treatment with AICAR significantly reduced both cyclin D1 and cyclin E compared with respective control and rTGF-␤-stimulated conditions (Fig. 4, A  and B) . Both cyclin E-associated CDK2 and cyclin D1-associated CDK4 were significantly elevated by rTGF-␤ but were completely reversed to below basal levels with concomitant AICAR (Fig. 4, C and D) . Intriguingly, no change was observed in cyclin D-associated CDK6, possibly suggesting that rTGF-␤ promotes cell cycle progression in a sequential cyclin D/CDK4-and cyclin E/CDK2-specific fashion. Furthermore, [at optimal multiplicity of infection (MOI)] for 6 h, quiesced overnight, and grown in complete media for 24 h after which expression of GFP (A) and Smad 3 (B) was analyzed by immunofluorescent flow cytometry and In-Cell Westerns. Inset: GFP expression in Ad-GFP-infected VSMCs after 24 h treatment. Smad3-and GFP-overexpressing cells were treated with/without AICAR (1 mM), after which cell cycle progression was analyzed after 24 h (C), and viable cell numbers were quantified by automated cell counting with trypan blue exclusion staining to estimate cytotoxicity after 48 h (D). Three independent experiments were performed, each in triplicate. ***P Ͻ 0.001 compared with vehicle control cells and #P Ͻ 0.001 compared with Ad-Smad3-treated cells.
AICAR elevated both CDK-I p21 and p27, yet only p21 remained significantly elevated following cotreatment with rTGF-␤ (Fig. 4, F and G) . Together, these data suggest that AMPK has the ability to inhibit rTGF-␤-induced cell cycle progression via reduction in G 0 /G 1 cyclin D/CDK4 and cyclin E/CDK2 complexes possibly through CDK inhibition via increased p21.
Regarding potential concerns with commercial or repeatedly passaged cells compared with primary preparations, it should be noted that initial experiments incorporated commercial A7R5 rat aortic VSMCs as well as primary rat aortic VSMCs, and their responsiveness to exogenous rTGF-␤ and AICAR stimulation were compared. Results show remarkable similarities between commercial and primary VSMCs in the ability of rTGF-␤ to induce downstream Smad3 phosphorylation (Fig.  1) . Additionally, comparable findings were observed between commercial and primary cells in the ability for rTGF-␤ to induce cell cycle progression and to increase cell numbers and the ability for AICAR to reverse these effects (Fig. 3) . Also, neither baseline nor AICAR-stimulated activation of AMPK nor phosphorylation of its downstream targets, acetyl-CoA carboxylase and vasodilator-stimulated phosphoprotein, were markedly different in commercial cells compared with primary cells as previously reported (23, 24) . Thus, data presented in this study using commercial cells mimic those observed in primary preparations and are considered sound, translatable, and biologically relevant.
In summary, findings in this study provide support for a discrete signaling network by which AMPK inhibits growthpromoting actions of TGF-␤/Smad3, and this concept is presented as a theoretical schematic in Fig. 6 . We propose that AMPK inhibits pSmad2/3 by promoting Smad7. Resulting inhibition of TGF-␤/Smad signaling leads to reversal of G 0 /G 1 cell cycle progression via inhibition of cyclins/CDKs D/4 and E/2 that we suggest is mediated by cytostatic p21. Cumulatively, these data highlight a novel and biologically important signaling cascade by which a metabolically activated protein such as AMPK has capability to inhibit cytokine-induced progrowth signaling events. This has clear biological importance as a therapeutically desirable approach to reverse vascular cell growth associated with disease.
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Cyc E plasma membrane Fig. 6 . Schematic depicting the proposed inhibitory actions of AICAR-stimulated AMPK on TGF-␤1-induced VSMC growth. Data presented in this study suggest that AICAR-stimulated AMPK has the ability to inhibit TGF-␤1-mediated Smad signaling via promoting inhibitory Smad7 and by preventing growth-promoting Smad2/Smad3. Prevention of Smad2/3 phosphorylation and oligomerization with Smad4 prevents their nuclear translocation and transcriptome activation of growth regulatory genes. We propose a possible prosynthetic mechanism of TGF-␤1/Smad signaling in VSMCs in the promotion of cell cycle progression and cell proliferation through cyclin D/CDK4 and cyclin E/CDK2. Additionally, AMPK possesses the ability to enhance the CDK inhibitor p21 that acts to further inhibit TGF-␤1-mediated G0/G1 cell cycle progression. Solid lines, signaling events previously characterized in the literature; broken lines, signaling events supported by new findings from this study.
